Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor

Clinical Trial Grant

Duke Scholars

Principal Investigator Richard Francis Riedel Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

June 29, 2020

End Date

April 4, 2024

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

June 29, 2020

End Date

April 4, 2024